Table 5 Summary of emergent adverse events: safety population
|  | Chondroitin sulfate (n = 97) | Celecoxib (n = 97) | p valuea | ||
|---|---|---|---|---|---|
Events | n (%) | Events | n (%) | ||
At least one AE | 305 | 78 (80.4) | 299 | 77 (79.4) | >0.999 |
Intensity | |||||
 Mild | 203 | 61 (62.9) | 215 | 61 (62.9) | 1.000 |
 Moderate | 89 | 47 (48.5) | 68 | 41 (42.3) | 0.471 |
 Severe | 13 | 9 (9.3) | 16 | 10 (10.3) | >0.999 |
SAE | 16 | 10 (10.3) | 9 | 6 (6.2) | 0.435 |
Relationship to study treatment | |||||
 Not related | 246 | 67 (69.1) | 241 | 68 (70.1) | >0.999 |
 Uncertain | 20 | 14 (14.4) | 23 | 13 (13.4) | >0.999 |
 Relatedb | 39 | 27 (27.8) | 35 | 24 (24.7) | 0.745 |
AE that led to study withdrawal | 13 | 13 (13.4) | 12 | 11 (11.3) | 0.828 |
Ongoingc | 95 | 50 (51.5) | 100 | 50 (51.5) | 1.000 |